



PARTICIPANT STATISTICS

HEPATITIS MARKERS

THIRD QUADRIMESTER 2011

| anti-HCV | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | | | | |
|-----------------------------|------------|----------|----------|------------|----------|----------|------------|----------|-----------|------------|----------|----------|------------|----------|----------|-------|--|--|
| | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | | | |
| Abbott Architect | 7 | | | 7 | | | | | | 7 | 7 | | | 7 | | | | |
| Abbott AxSYM | 10 | | | 10 | | | | | 10 | 10 | | | | 10 | | | | |
| J&J Vitros | 8 | | | 8 | | | | | 8 | 8 | | | | 8 | | | | |
| Ortho HCV Version 3.0 ELISA | 18 | | | 18 | | | | | 18 | 18 | | | | 17 | 1 | | | |
| Roche Cobas/Elecsys | 1 | 1 | 2 | 4 | | | | | 4 | 1 | 2 | 1 | | 4 | | | | |
| Siemens Advia | 6 | | | 6 | | | | | 6 | 6 | | | | 6 | | | | |
| Total Population | 57 | 1 | 2 | 60 | 0 | 0 | 0 | 0 | 60 | 57 | 2 | 1 | 59 | 1 | 0 | | | |
| Flagging | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | |

| anti-HBc IgG + IgM | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | | | | |
|----------------------------|------------|----------|-----------|------------|----------|-----------|------------|----------|----------|------------|----------|----------|------------|----------|-----------|-------|--|--|
| | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | | | |
| Abbott AxSYM Core | | | 7 | | | 7 | 7 | | | 7 | | | | | 7 | | | |
| Bio-Rad MONOLISA EIA | | | 5 | | | 5 | 5 | | | 5 | | | | | 5 | | | |
| DiaSorin ETI-AB-COREK/Plus | | | 4 | | | 4 | 4 | | | 4 | | | | | 4 | | | |
| J&J Vitros | | | 6 | | | 6 | 6 | | | 6 | | | | | 6 | | | |
| Siemens Advia | | | 4 | | | 4 | 4 | | | 4 | | | | | 4 | | | |
| Siemens Immulite 2000 | | | 5 | | | 5 | 5 | | | 4 | 1 | | | | 5 | | | |
| Total Population | 0 | 0 | 35 | 0 | 0 | 35 | 35 | 0 | 0 | 34 | 1 | 0 | 0 | 0 | 35 | | | |
| Flagging | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | |

| anti-HBc IgM | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | | | | |
|-----------------------------|------------|----------|----------|------------|----------|----------|------------|----------|----------|------------|----------|----------|------------|----------|----------|-------|--|--|
| | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | | | |
| Abbott Core-M | 4 | | | 4 | | | 4 | | | 4 | | | | | 4 | | | |
| Bio-Rad MONOLISA EIA | 4 | | | 4 | | | 4 | | | 4 | | | | 1 | 3 | | | |
| DiaSorin ETI-CORE-IGMK Plus | 3 | 1 | | 4 | | | 4 | | | 4 | | | | 2 | 2 | | | |
| J&J Vitros | 4 | | | 4 | | | 4 | | | 4 | | | | 4 | | | | |
| Siemens Advia | | | 3 | | | 3 | 3 | | | 3 | | | | | 3 | | | |
| Siemens Immulite | 6 | | | 6 | | | 6 | | | 6 | | | | 4 | 1 | | | |
| Total Population | 22 | 1 | 4 | 23 | 0 | 4 | 27 | 0 | 0 | 27 | 0 | 0 | 16 | 1 | 9 | | | |
| Flagging | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | |

Due to lack of participant consensus, Specimen 5 was not evaluated this event.

| anti-HBs | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | | | | |
|--------------------------|------------|----------|-----------|------------|----------|-----------|------------|----------|----------|------------|----------|-----------|------------|----------|----------|-------|--|--|
| | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | | | |
| Abbott Architect | | | 6 | | | 6 | 6 | | | | | 6 | | 6 | | | | |
| Abbott AxSYM AUSAB | | | 6 | | | 6 | 6 | | | | | 6 | | 6 | | | | |
| Bio-Rad MONOLISA EIA | | | 5 | | | 5 | 5 | | | | | 5 | | 5 | | | | |
| DiaSorin ETI-AB-AUK Plus | | | 7 | | | 7 | 7 | | | | | 7 | | 7 | | | | |
| J&J Vitros | | | 6 | 1 | | 5 | 6 | | | | | 6 | | 6 | | | | |
| Roche Elecsys | | | 13 | | | 13 | 13 | | | | | 13 | | 13 | | | | |
| Siemens Advia | | | 4 | | | 4 | 4 | | | | | 4 | | 4 | | | | |
| Siemens Immulite | 1 | 1 | 7 | 1 | 1 | 7 | 9 | | | 1 | 1 | 7 | | 8 | 1 | | | |
| Total Population | 1 | 1 | 55 | 2 | 1 | 54 | 57 | 0 | 0 | 1 | 1 | 55 | 56 | 1 | 1 | | | |
| Flagging | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | |

| anti-HBeAg | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | | | | |
|-------------------------|------------|----------|----------|------------|----------|----------|------------|----------|----------|------------|----------|----------|------------|----------|----------|-------|--|--|
| | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | Neg | Ind | Pos | | | |
| DiaSorin ETI-EBK Plus | 4 | | | 4 | | | 4 | | | 4 | | | | | 4 | | | |
| General Biologicals Co | 1 | | | 1 | | | 1 | | | 1 | | | | 1 | | | | |
| Total Population | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 1 | 0 | 4 | | | |
| Flagging | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | |

| HBsAg | Specimen 1 | | | Specimen 2 | | | Specimen 3 | | | Specimen 4 | | | Specimen 5 | | | | | |
|---------------------------|------------|----------|----------|------------|-------------------|----------|------------|-------------------|----------|------------|----------|----------|------------|-------------------|----------|-------|--|--|
| | Neg | Ind | Pos | Neg | Reac. Would Refer | Pos | Neg | Reac. Would Refer | Pos | Neg | Ind | Pos | Pos | Reac. Would Refer | Ind | | | |
| Abbott Architect | 9 | | | 9 | | | 9 | | | 9 | | | | 9 | | | | |
| Abbott ImX/AxSYM | 6 | | | 5 | 1 | | 6 | | | 6 | | | | 3 | 3 | | | |
| Bio-Rad EIA-Proc A | 8 | | | 8 | | | 8 | | | 8 | | | | 8 | | | | |
| Bio-Rad MONOLISA AgHBs + | 4 | | | 4 | | | 4 | | | 4 | | | | 3 | 1 | | | |
| Bio-Rad MONOLISA Ultra | 3 | | | 3 | | | 3 | | | 3 | | | | 3 | | | | |
| DiaSorin ETI-MAK-2 Plus | 7 | | | 7 | | | 7 | | | 7 | | | | 7 | | | | |
| DiaSorin ETI-MAK-2 Proc A | 3 | | | 3 | | | 3 | | | 3 | | | | 3 | | | | |
| General Biologicals Co | 1 | | | 1 | | | 1 | | | 1 | | | | 1 | | | | |
| J&J Vitros ECI | 9 | | | 8 | | 1 | 9 | | | 9 | | | | 9 | | | | |
| Roche Elecsys | 14 | | | 14 | | | 14 | | | 14 | | | | 8 | 5 | | | |
| Siemens Advia | 7 | | | 7 | | | 7 | | | 7 | | | | 6 | 1 | | | |
| Siemens Immulite | 22 | | | 22 | | | 22 | | | 21 | | 1 | 14 | 6 | 1 | | | |
| Total Population | 96 | 0 | 0 | 92 | 1 | 2 | 95 | 0 | 1 | 95 | 0 | 1 | 77 | 16 | 2 | | | |
| Flagging | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | | ***** | | |

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.